Problem

Drug development is constrained by the difficulty of precisely constructing complex molecules, the risk of off-target toxicity, and the limitations of relying on binding-based mechanisms alone. Conventional protein and enzyme engineering also requires large experimental datasets and long design cycles; Ridge says its cell-free approach can generate up to a million-fold more sequence-function data than conventional methods and compress work that once took years into weeks. The economics are therefore tied to faster discovery, fewer failed designs, and better therapeutic performance.

Ridge’s clearest use case is next-generation antibody-drug conjugates (ADCs). Existing conjugation methods can create stability, manufacturing, and functional challenges, while payloads that affect healthy tissue can limit a drug’s therapeutic window. Ridge targets those problems by enabling more homogeneous antibody modification and conditionally activating payloads in tumors, with the goal of reducing off-tumor toxicity and unlocking targets that conventional ADCs cannot safely address.

Product / Service

Ridge Bio combines proprietary machine-learning models with high-throughput, cell-free experimentation to design precision enzymes and targeted delivery systems. It appears to operate as a platform and partner-led technology business: drug developers can use Ridge’s engineered biocatalysts, linkers, and discovery capabilities across ADCs, targeted nucleic-acid delivery, in-vivo CAR-T, radiotherapies, biocatalysis, and enzyme therapeutics.

Its initial product lines are NativeLink enzymes and ProTrigger linkers. NativeLink-AXC site-specifically modifies native antibodies without changing their amino-acid sequences, glycans, disulfide bonds, or producing cell line; it can support user-defined drug-to-antibody ratios, multiple payloads, and direct upgrading of an existing ADC. ProTrigger consists of AI-designed, protease-cleavable linkers that activate or release payloads in target tissues, adding a conditional “AND” gate intended to improve safety and expand the range of addressable targets.

Market

Ridge competes in the emerging market for AI-enabled protein and enzyme design, precision therapeutics, next-generation bioconjugates, and ADC-enabling technologies. The company’s own materials emphasize three overlapping categories: site-specific conjugation, conditionally active drug delivery, and enzyme-based therapeutics. The reviewed launch materials do not name a direct competitor; the practical competitive set is therefore likely to include incumbent or in-house bioconjugation platforms, alternative protein-design technologies, and other suppliers of ADC linkers and conjugation systems.

Ridge is an early-stage company rather than a proven commercial drug developer. Founded in 2024, it emerged from stealth in September 2025 with an oversubscribed $25 million seed round led by Sutter Hill Ventures, launched NativeLink and ProTrigger, and announced a collaboration with an ADC-focused biotech. It also reported early interest from biopharma companies and CDMOs, but the available materials disclose no revenue, marketed product, or clinical-stage asset, so its traction is best characterized as funded platform validation and partnership activity rather than established commercial revenue.